Abstract | BACKGROUND: METHODS: Patients were treated with bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m(2) on days 1, 8, and 15 of a 28-day cycle until progressive disease (PD) or excessive toxicity. The primary endpoint was progression-free survival (PFS); secondary objectives included overall survival (OS), objective response, and toxicity. RESULTS: Patients (N = 40) received a median of 8 treatment cycles. Toxicity was generally mild or moderate, with neutropenia (18%), hypertension (20%), gastrointestinal toxicity (18%), pain (13%), metabolic toxicity (15%), bowel obstruction (10%), and cardiotoxicity (8%) being the most common grade 3 and 4 adverse events. No bowel perforations, febrile neutropenia, or treatment-related deaths occurred. Median PFS and OS were 7.8 (95% confidence interval [CI], 3.0-9.4) and 16.6 months (95% CI, 12.8-22.9), with 22 (55%) patients progression-free for ≥6 months. Ten (25%) patients had partial response (PR), 14 (35%) had stable disease (SD), and 16 (40%) had PD. Patients treated with 2 prior regimens received greater benefit than patients treated with 1: PR/SD, 78.9% versus 42.9% (P = .03); median PFS, 10.9 versus 2.8 months (P = .08); median OS, 22.9 versus 12.8 months (P = .02). CONCLUSIONS: A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum-resistant OC; further study is warranted.
|
Authors | Kathryn F McGonigle, Howard G Muntz, Jacqueline Vuky, Pamela J Paley, Dan S Veljovich, Benjamin E Greer, Barbara A Goff, Heidi J Gray, Thomas W Malpass |
Journal | Cancer
(Cancer)
Vol. 117
Issue 16
Pg. 3731-40
(Aug 15 2011)
ISSN: 1097-0142 [Electronic] United States |
PMID | 21815133
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Platinum Compounds
- Bevacizumab
- Topotecan
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Fallopian Tube Neoplasms
(drug therapy)
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy)
- Peritoneal Neoplasms
(drug therapy)
- Platinum Compounds
(pharmacology)
- Topotecan
(administration & dosage)
|